BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 19424629)

  • 1. Expression analysis of VEGF-A and VEGF-B: relationship with clinicopathological parameters in bladder cancer.
    Fauconnet S; Bernardini S; Lascombe I; Boiteux G; Clairotte A; Monnien F; Chabannes E; Bittard H
    Oncol Rep; 2009 Jun; 21(6):1495-504. PubMed ID: 19424629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression.
    Quentin T; Schlott T; Korabiowska M; Käthei N; Zöller G; Glaser F; Kunze E
    Anticancer Res; 2004; 24(5A):2745-56. PubMed ID: 15517881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transient receptor potential vanilloid type 2 (TRPV2) expression in normal urothelium and in urothelial carcinoma of human bladder: correlation with the pathologic stage.
    Caprodossi S; Lucciarini R; Amantini C; Nabissi M; Canesin G; Ballarini P; Di Spilimbergo A; Cardarelli MA; Servi L; Mammana G; Santoni G
    Eur Urol; 2008 Sep; 54(3):612-20. PubMed ID: 17977643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder.
    Izawa JI; Slaton JW; Kedar D; Karashima T; Perrotte P; Czerniak B; Grossman HB; Dinney CP
    Oncol Rep; 2001; 8(1):9-15. PubMed ID: 11115562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HMOX1 is an important prognostic indicator of nonmuscle invasive bladder cancer recurrence and progression.
    Yim MS; Ha YS; Kim IY; Yun SJ; Choi YH; Kim WJ
    J Urol; 2011 Feb; 185(2):701-5. PubMed ID: 21168882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bladder Tumor Subtype Commitment Occurs in Carcinoma
    Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
    Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Large-scale real-time reverse transcription-PCR approach of angiogenic pathways in human transitional cell carcinoma of the bladder: identification of VEGFA as a major independent prognostic marker.
    Pignot G; Bieche I; Vacher S; Güet C; Vieillefond A; Debré B; Lidereau R; Amsellem-Ouazana D
    Eur Urol; 2009 Oct; 56(4):678-88. PubMed ID: 18513850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
    Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
    J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
    Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
    J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential expression of vascular endothelial growth factor165b in transitional cell carcinoma of the bladder.
    Das K; Zhao Y; Sugiono M; Lau W; Tan PH; Cheng C
    Urol Oncol; 2007; 25(4):317-21. PubMed ID: 17628298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Qualitative and quantitative analysis of angiogenetic factors in transitional cell bladder carcinoma: relationship with clinical course at 10 years follow-up.
    Bartoletti R; Cai T; Nesi G; Sardi I; Rizzo M
    Oncol Rep; 2005 Jul; 14(1):251-5. PubMed ID: 15944797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma.
    Tsui KH; Cheng AJ; Chang Pe; Pan TL; Yung BY
    Urology; 2004 Oct; 64(4):839-44. PubMed ID: 15491744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GPX2 underexpression indicates poor prognosis in patients with urothelial carcinomas of the upper urinary tract and urinary bladder.
    Chang IW; Lin VC; Hung CH; Wang HP; Lin YY; Wu WJ; Huang CN; Li CC; Li WM; Wu JY; Li CF
    World J Urol; 2015 Nov; 33(11):1777-89. PubMed ID: 25813210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and function analysis of indoleamine 2 and 3-dioxygenase in bladder urothelial carcinoma.
    Yang C; Zhou Y; Zhang L; Jin C; Li M; Ye L
    Int J Clin Exp Pathol; 2015; 8(2):1768-75. PubMed ID: 25973066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of vascular endothelial growth factor isoforms and platelet-derived endothelial cell growth factor in bladder cancer.
    Li N; Kanda K; Fukumori T; Inoue Y; Nishitani M; Kanayama H; Kagawa S
    Urol Oncol; 2000 Dec; 6(1):10-15. PubMed ID: 11113367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression.
    Crew JP; Fuggle S; Bicknell R; Cranston DW; de Benedetti A; Harris AL
    Br J Cancer; 2000 Jan; 82(1):161-6. PubMed ID: 10638984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue.
    Shen SS; Smith CL; Hsieh JT; Yu J; Kim IY; Jian W; Sonpavde G; Ayala GE; Younes M; Lerner SP
    Cancer; 2006 Jun; 106(12):2610-6. PubMed ID: 16700038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic regulation of vascular endothelial growth factor a dynamic expression in transitional cell carcinoma.
    Ping SY; Shen KH; Yu DS
    Mol Carcinog; 2013 Jul; 52(7):568-79. PubMed ID: 22392726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stage, grade and behavior of bladder urothelial carcinoma defined by the microRNA expression profile.
    Dip N; Reis ST; Timoszczuk LS; Viana NI; Piantino CB; Morais DR; Moura CM; Abe DK; Silva IA; Srougi M; Dall'Oglio MF; Leite KR
    J Urol; 2012 Nov; 188(5):1951-6. PubMed ID: 22999546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DDR2 overexpression in urothelial carcinoma indicates an unfavorable prognosis: a large cohort study.
    Tsai MC; Li WM; Huang CN; Ke HL; Li CC; Yeh HC; Chan TC; Liang PI; Yeh BW; Wu WJ; Lim SW; Li CF
    Oncotarget; 2016 Nov; 7(48):78918-78931. PubMed ID: 27793038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.